NCT00940420View on ClinicalTrials.gov

A Study of Combination Treatment With Pegasys (Peginterferon Alfa) and Copegus (Ribavirin)in Patients With Chronic Hepatitis C

PHASE4CompletedINTERVENTIONAL
Enrollment

2,695

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions
Hepatitis C, Chronic
Interventions
DRUG

Copegus (ribavirin)

800 - 1200 mg po daily for 24 weeks

DRUG

Copegus (ribavirin)

800 - 1200 mg po daily for 48 weeks

DRUG

peginterferon alfa-2a [Pegasys]

180 mcg sc once weekly for 24 weeks

DRUG

peginterferon alfa-2a [Pegasys]

180 mcg sc once weekly for 48 weeks

Trial Locations (20)

13110

Safed

18101

Afula

22100

Nahariya

31096

Haifa

33394

Haifa

34362

Haifa

38100

Hadera

44281

Kfar Saba

49100

Petah Tikva

52621

Ramat Gan

58100

Holon

76100

Rehovot

78278

Ashkelon

84105

Beersheba

91120

Jerusalem

6093000

Ẕerifin

6423906

Tel Aviv

Unknown

Bat Yam

Nazareth

Petah Tikva

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00940420 - A Study of Combination Treatment With Pegasys (Peginterferon Alfa) and Copegus (Ribavirin)in Patients With Chronic Hepatitis C | Biotech Hunter | Biotech Hunter